Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 3 (KIR3DL3)
- Target
- KIR3DL3
- Molecular classification
- Receptor, Transmembrane glycoprotein, Immunoglobulin superfamily
01
Overview
Killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3) is an inhibitory receptor primarily expressed on subsets of T cells, especially γδ T cells and CD8+ T cells, and terminally differentiated effector memory NK cells. It interacts with HHLA2, a B7 family member, mediating co-inhibition of immune responses. KIR3DL3 acts as an immune checkpoint, and blockade of the KIR3DL3-HHLA2 interaction can enhance anti-tumor immunity. The gene is highly polymorphic, affecting expression levels, making it relevant to personalized medicine approaches.
02
Mechanism of action
Blockade of KIR3DL3-HHLA2 interaction to reinvigorate anti-tumor immunity
03
Biological functions
Immune responseInhibitory signalingT cell regulationNK cell regulation
04
Disease associations
CancerImmune evasion
05
Safety considerations
Potential for autoimmunity due to immune checkpoint blockadeIndividual variability in KIR3DL3 expression due to genetic polymorphism
06
Biomarkers
HHLA2 expression levels in tumorsKIR3DL3 expression levels on immune cells
Beyond the preview
Go deeper on Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 3 (KIR3DL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 3 (KIR3DL3).